Thanks for taking the time to summarize the IPIX m

Thanks for taking the time to summarize the IPIX meeting. I concur with your comments.

The oral Brillacidin for Ulcerative Colitis trial starting in December and going " quickly." Is very significant. IMO Brilacidin for Ulcerative Colitis has the potential to be a paradigm shift in the management of not only Ulcerative Colitis but many other intestinal disorders. It represents an extremely large market.with toxic treatments which are often ineffective. A friend of mine underwent a complete colectomy a few weeks ago after failing all standard treatments and a couple of clinical trials

The comment , " BP told them that if they can show them a successful 2a, they will be “knocking their door down.“ is not an exaggeration; the trial and subsequent positive trials could be a company maker.

I was surprised there were no comments or questions concerning the insertion of the Novartis BDD PR link in the IPIX PR from 9/16/2019

http://www.ipharminc.com/press-release/2019/9...-the-colon

There has been no correction or retraction so it is not an oversight. Two interpretations are possible:

1. IPIX wanted readers to understand a large BP is interested in the BDD technology, too {for an undisclosed project}
2 IPIX wanted readers to infer a link between Novartis and IPIX

With Bertilino's background{and he is still here}, the Irish office and interest in combining EU trials with FDA trials I have felt Novartis would be a logical choice for a big Pharma partner.

And last of all, “Leo said that he will provide more clarity in the coming weeks. “A new direction, a new understanding of what’s going on, actually growing the company, not shrinking it.

A real riddle, is he hinting at a possible merger? Perhaps that is what will require extra shares.

IPIX shareholders have much to anticipate.

GLTA, Farrell